Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce the results of voting at its 2022 Annual General Meeting of Shareholders held on June 23, 2022 (the “Meeting”).
June 23, 2022
· 1 min read